Management of pediatric acute hematogenous osteomyelitis, part II: a focus on methicillin-resistant Staphylococcus aureus, current and emerging therapies.
Pharmacotherapy. 2018 Jul 10;:
Authors: DeRonde KJ, Girotto JE, Nicolau DP
Methicillin-resistant Staphylococcus aureus (MRSA) has become the most prevalent cause of acute hematogenous osteomyelitis (AHO) in pediatric patients. This increase in MRSA is due to the rise in community-acquired-MRSA. Therefore, it is important that clinicians are aware of the various and upcoming therapies that cover this bacterium. A literature search of the MEDLINE® database was performed from creation through January 2018. Articles chosen for the review emphasize well-established MRSA treatment options for pediatric AHO, newer therapies on the horizon, and important pharmacokinetics and pharmacodynamic concepts for treatment. Traditional therapies, including vancomycin and clindamycin, remain effective for the treatment of pediatric AHO. When these agents cannot be utilized, evidence in AHO has been growing for daptomycin, linezolid, and ceftaroline. Further initial pediatric data with the long-acting lipoglycopeptides show promise and in the future, may provide a role in AHO treatment in children. This article is protected by copyright. All rights reserved.
PMID: 29989190 [PubMed - as supplied by publisher]